CompletedPhase 3

Study to Evaluate Potential Decrease in Hospitalization Events, Time Between Events, and Increasing Longevity in Patients With Symptomatic Heart Failure (0954-948)

3,834 participantsStarted 2001-12-19

Plain-language summary

This is a multicenter study to evaluate potential decrease in hospitalization events and time between events and increasing longevity in patients with symptomatic congestive heart failure and intolerant of first-line medication for heart failure. This study will evaluate if higher doses of the investigational drug given daily will be superior to the lower dose of the same investigational drug given daily.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Symptomatic heart failure with known or recently diagnosed intolerance of treatment with first-line medication for heart failure * May or may not be receiving an alternative and/or additional drug treatment

What they're measuring

Number of Participants That Experienced One Component of the Composite Clinical Endpoint of All Cause Death or Hospitalization for Heart Failure

Timeframe: Entire follow-up (median = 4.7 years)

Trial details

NCT IDNCT00090259

SponsorOrganon and Co

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2009-03-31

Results submitted2010-06-30

View on ClinicalTrials.gov More Heart Failure trials